Tularik Inc. (ticker: TLRK, exchange: NASDAQ) News Release - 25-Mar-2003
--------------------------------------------------------------------------------
Tularik Announces Initiation of Pivotal Trial of T67 for the Treatment of Hepatocellular Carcinoma; Global Development Program Underway
SOUTH SAN FRANCISCO, Calif., Mar 25, 2003 (BUSINESS WIRE) -- Tularik Inc. (Nasdaq:TLRK) announced the enrollment of the first patient in the registration trial for T67, a drug candidate being developed for the treatment of hepatocellular carcinoma (HCC), a leading cause of cancer death worldwide.
Tularik is conducting a two-arm, randomized, global study to compare the survival of patients who receive T67 versus those receiving doxorubicin. Doxorubicin is the current systemic chemotherapy standard of care for HCC, although the FDA has not approved it for this indication. Tularik plans to enroll up to 750 chemotherapy-naive patients in up to 75 sites in the US and abroad. The primary goal of the study will be to determine whether there is a benefit in the patients treated with T67 compared to doxorubicin.
"The initiation of this pivotal study represents another major step in our efforts to bring T67 to market," stated Dr. Michael Levy, Vice President, Development and Chief Medical Officer of Tularik. "There are currently no approved systemic therapies for HCC, so we urgently want to address this unmet medical need." |
